{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-004404","form_type":"8-K","ticker":"UFPT","cik":"0000914156","company_name":"UFP TECHNOLOGIES INC","filed_at":"2024-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.290595+00:00","generated_at":"2026-05-31T13:34:36.386112+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"UFP Technologies Q2 net income $13.6M ($1.75 EPS), revenue up 10% to $110.2M; acquires three firms","bullets":["Net income $13.6M ($1.75 diluted EPS) vs $11.9M ($1.55) in Q2 2023, up 14.0%.","Q2 revenue $110.2M (+10.1% YoY), driven by robotic surgery and infection prevention markets.","Completed three acquisitions (Marble Medical, AJR Enterprises, Welch Fluorocarbon) adding ~$90M revenue and $20M EBITDA.","New $275M credit facility; pro-forma leverage ~1.8x post-acquisitions.","Gross margin improved to 30.0% from 29.6%; SG&A increased to 12.6% of sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-004404","json":"https://secwatch.observer/filing/0001171843-24-004404.json","markdown":"https://secwatch.observer/filing/0001171843-24-004404.md","text":"https://secwatch.observer/filing/0001171843-24-004404.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914156/000117184324004404/0001171843-24-004404-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914156/000117184324004404/f8k_080224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:34:36.386112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}